61
CanSino Biologics Inc.
6185.HK · HKSE
$29.60 +3.86% (+$1.10)
1M +16.42%
Market Cap ¥8.80B
P/E Ratio 216.55x
Div. Yield -
ROE 0.82%
Piotroski F-Score Moderate
6/9Valuation
16 /100
Expensive P/E 216.55x
EV/EBITDA 225.42x
P/S 7.17x
Growth
16 /100
Declining Rev. growth 0.03%
Book val. growth 9.78%
EPS growth N/A
Profitability
25 /100
Weak Gross margin 71.69%
Net margin 3.31%
Op. margin 4.62%
Quality
4 /100
Poor ROIC 0.82%
ROE 0.82%
ROA 0.59%
Debt
80 /100
Low Debt/Equity 0.20x
Current ratio 4.39x
Int. coverage -2.08x
Stability
18 /100
Unstable Beta 1.22x
Rev. volatility 106.33%
EPS volatility 90.50%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6185.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Xue Feng Yu
Employees
1,134
Headquarters
Tianjin
Upcoming events
02 NOV
Earnings
Upcoming earnings report
30 MAR
Earnings
Upcoming earnings report